JP2017531613A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017531613A5 JP2017531613A5 JP2017500335A JP2017500335A JP2017531613A5 JP 2017531613 A5 JP2017531613 A5 JP 2017531613A5 JP 2017500335 A JP2017500335 A JP 2017500335A JP 2017500335 A JP2017500335 A JP 2017500335A JP 2017531613 A5 JP2017531613 A5 JP 2017531613A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- polypeptide
- subject
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462059682P | 2014-10-03 | 2014-10-03 | |
| US62/059,682 | 2014-10-03 | ||
| PCT/US2015/053700 WO2016054494A1 (en) | 2014-10-03 | 2015-10-02 | Methods and compositions for treatment of conditions associated with elevated triglycerides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017531613A JP2017531613A (ja) | 2017-10-26 |
| JP2017531613A5 true JP2017531613A5 (https=) | 2018-11-08 |
| JP6680758B2 JP6680758B2 (ja) | 2020-04-15 |
Family
ID=55631597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017500335A Expired - Fee Related JP6680758B2 (ja) | 2014-10-03 | 2015-10-02 | 上昇したトリグリセリドと関連する状態の治療のための方法及び組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US10071139B2 (https=) |
| EP (2) | EP3822287A1 (https=) |
| JP (1) | JP6680758B2 (https=) |
| AU (1) | AU2015327900B2 (https=) |
| CA (1) | CA2954082A1 (https=) |
| ES (1) | ES2819866T3 (https=) |
| WO (1) | WO2016054494A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3822287A1 (en) | 2014-10-03 | 2021-05-19 | NGM Biopharmaceuticals, Inc. | Angptl8 polypeptide and its use for treatment of conditions associated with elevated triglycerides |
| TW201713690A (zh) * | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗ａｎｇｐｔｌ８抗體及其用途 |
| MX2018009513A (es) * | 2016-02-04 | 2019-01-31 | Regeneron Pharma | Animales no humanos que tienen un gen angptl8 modificado genéticamente. |
| JP7541810B2 (ja) | 2016-03-03 | 2024-08-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法 |
| WO2017168348A1 (en) * | 2016-03-31 | 2017-10-05 | Baylor Research Institute | Angiopoietin-like protein 8 (angptl8) |
| KR20180132843A (ko) * | 2016-04-08 | 2018-12-12 | 리제너론 파아마슈티컬스, 인크. | Angptl8 억제제 및 angptl3 억제제로 고지혈증을 치료하는 방법 |
| WO2018094112A1 (en) | 2016-11-17 | 2018-05-24 | Regeneron Pharmaceuticals, Inc. | Methods of treating obesity with anti-angptl8 antibodies |
| CA3080148A1 (en) | 2017-11-10 | 2019-05-16 | Ngm Biopharmaceuticals, Inc. | Angptl8-binding agents and methods of use thereof |
| US11977081B2 (en) | 2017-12-18 | 2024-05-07 | Regeneron Pharmaceuticals, Inc. | ANGPTL8 assay and uses thereof |
| TWI747098B (zh) * | 2018-12-21 | 2021-11-21 | 美商美國禮來大藥廠 | 抗angptl3/8複合物抗體及其使用方法 |
| US12559551B2 (en) | 2019-05-24 | 2026-02-24 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-ANGPTL3 antibodies |
| CN110694068A (zh) * | 2019-11-06 | 2020-01-17 | 北京市心肺血管疾病研究所 | 一种抑制血管生成素样蛋白8的物质的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US20050100991A1 (en) * | 2001-04-12 | 2005-05-12 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP2261250B1 (en) * | 2001-12-21 | 2015-07-01 | Human Genome Sciences, Inc. | GCSF-Albumin fusion proteins |
| WO2011084714A2 (en) | 2009-12-17 | 2011-07-14 | Biogen Idec Ma Inc. | STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF |
| US20140303078A1 (en) * | 2011-06-10 | 2014-10-09 | President And Fellows Of Harvard College | Modulation of pancreatic beta cell proliferation |
| CN105073781A (zh) | 2013-01-11 | 2015-11-18 | 加州生物医学研究所 | 牛融合抗体 |
| CN105813654B (zh) | 2013-10-11 | 2019-05-31 | 美国政府(由卫生和人类服务部的部长所代表) | Tem8抗体及其用途 |
| EP3822287A1 (en) | 2014-10-03 | 2021-05-19 | NGM Biopharmaceuticals, Inc. | Angptl8 polypeptide and its use for treatment of conditions associated with elevated triglycerides |
| TW201713690A (zh) | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗ａｎｇｐｔｌ８抗體及其用途 |
| WO2018094112A1 (en) | 2016-11-17 | 2018-05-24 | Regeneron Pharmaceuticals, Inc. | Methods of treating obesity with anti-angptl8 antibodies |
| CA3080148A1 (en) | 2017-11-10 | 2019-05-16 | Ngm Biopharmaceuticals, Inc. | Angptl8-binding agents and methods of use thereof |
-
2015
- 2015-10-02 EP EP20185093.0A patent/EP3822287A1/en not_active Withdrawn
- 2015-10-02 CA CA2954082A patent/CA2954082A1/en active Pending
- 2015-10-02 JP JP2017500335A patent/JP6680758B2/ja not_active Expired - Fee Related
- 2015-10-02 WO PCT/US2015/053700 patent/WO2016054494A1/en not_active Ceased
- 2015-10-02 ES ES15848061T patent/ES2819866T3/es active Active
- 2015-10-02 US US15/318,937 patent/US10071139B2/en active Active
- 2015-10-02 EP EP15848061.6A patent/EP3201225B1/en active Active
- 2015-10-02 AU AU2015327900A patent/AU2015327900B2/en not_active Ceased
-
2018
- 2018-08-06 US US16/056,068 patent/US10702587B2/en not_active Expired - Fee Related
-
2020
- 2020-05-29 US US16/888,249 patent/US20210015902A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017531613A5 (https=) | ||
| JP7474729B2 (ja) | 肺高血圧症を治療するための組成物および方法 | |
| US20220162283A1 (en) | Methods of treating skin tissue damage | |
| JP2014521684A5 (https=) | ||
| Chrysant et al. | Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors | |
| JP2019178132A5 (https=) | ||
| US10702587B2 (en) | Angiopoietin-like protein 8 polypeptide fragments and compositions thereof | |
| JP2010513506A5 (https=) | ||
| AU2020340618B2 (en) | Therapeutic fusion proteins | |
| JP2012509902A5 (https=) | ||
| CA2971414A1 (en) | Methods of treating tissue calcification | |
| Sarzani et al. | Adipocentric origin of the common cardiometabolic complications of obesity in the young up to the very old: pathophysiology and new therapeutic opportunities | |
| JP2017500316A5 (https=) | ||
| WO2013103972A1 (en) | Treatment of frailty syndrome and symptoms thereof | |
| CN102120755B (zh) | 一种棕色脂肪组织靶向性多肽及其应用 | |
| CN105079780A (zh) | 一种特异结合trb3的多肽在治疗或预防腹主动脉瘤中的应用 | |
| WO2018019840A1 (en) | Pharmaceutical compositions for the treatment of left ventricular hypertrophy and dysfunction associated to metabolic syndrome | |
| JP2017509602A5 (https=) | ||
| Moreno-Pérez et al. | Are we ready for an adipocentric approach in people living with type 2 diabetes and chronic kidney | |
| Yoo | Infliximab/mesalazine | |
| RU2022104898A (ru) | Слитый белок fgf21 fc, слитый белок glp-1 fc и комбинированный терапевтический агент, включающий их, и их применение | |
| Wagner et al. | Effect of liraglutide on physical performance in type 2 diabetes (LIPER2): a randomised, double-blind, controlled trial | |
| Pala et al. | Noninvasive evaluation of a giant circumflex coronary artery aneurysm fistulized into the coronary sinus by multislice computed tomography Koroner sinüse fistülize dev sirkumfleks koroner arter anevrizmasının çokkesitli bilgisayarlı tomografi ile noninvaziv değerlendirilmesi | |
| JP2018500386A5 (https=) |